Overview

A Study to Assess Efficacy, Safety of KAE609 in Adult Patients With Acute Malaria Mono-infection

Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
This study will assess efficacy, safety , tolerability and PK in uncomplicated adult malaria patients with acute P. falciparum infection after single dose with KAE609 at 75 mg, 150mg, 225mg and 300mg/day
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals